Zurcher Kantonalbank Zurich Cantonalbank grew its position in Allergan plc (NYSE:AGN) by 5.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 82,921 shares of the company’s stock after purchasing an additional 4,219 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Allergan were worth $15,795,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Thompson Siegel & Walmsley LLC boosted its stake in shares of Allergan by 3,032.4% in the second quarter. Thompson Siegel & Walmsley LLC now owns 877,740 shares of the company’s stock valued at $146,337,000 after buying an additional 849,719 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Allergan by 27,066.5% in the second quarter. Renaissance Technologies LLC now owns 787,828 shares of the company’s stock valued at $131,347,000 after buying an additional 784,928 shares during the period. Sound Shore Management Inc. CT bought a new stake in shares of Allergan in the third quarter valued at approximately $140,026,000. Mainstay Capital Management LLC ADV boosted its stake in shares of Allergan by 13,097.2% in the second quarter. Mainstay Capital Management LLC ADV now owns 675,039 shares of the company’s stock valued at $4,288,000 after buying an additional 669,924 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in shares of Allergan by 16.3% in the second quarter. Janus Henderson Group PLC now owns 4,778,699 shares of the company’s stock valued at $796,712,000 after buying an additional 668,343 shares during the period. 78.48% of the stock is currently owned by institutional investors.
Several equities research analysts recently issued reports on the company. Zacks Investment Research cut Allergan from a “hold” rating to a “sell” rating in a research note on Wednesday, October 3rd. ValuEngine upgraded Allergan from a “strong sell” rating to a “sell” rating in a research note on Friday, September 21st. TheStreet upgraded Allergan from a “d+” rating to a “c” rating in a research note on Monday, August 20th. Cowen set a $255.00 target price on Allergan and gave the stock a “buy” rating in a research note on Wednesday, October 17th. Finally, Cantor Fitzgerald restated a “hold” rating and set a $180.00 target price on shares of Allergan in a research note on Friday, September 14th. Two analysts have rated the stock with a sell rating, five have given a hold rating and eighteen have issued a buy rating to the company. Allergan currently has an average rating of “Buy” and an average target price of $209.18.
Allergan (NYSE:AGN) last announced its quarterly earnings results on Tuesday, October 30th. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.04 by $0.21. The company had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.89 billion. Allergan had a net margin of 14.50% and a return on equity of 8.44%. The company’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period in the prior year, the business earned $4.15 earnings per share. As a group, analysts predict that Allergan plc will post 16.49 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 14th. Stockholders of record on Tuesday, November 13th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, November 9th. This represents a $2.88 annualized dividend and a dividend yield of 1.87%. Allergan’s dividend payout ratio (DPR) is presently 17.61%.
In related news, Director Christopher J. Coughlin purchased 10,000 shares of the stock in a transaction dated Thursday, September 6th. The stock was bought at an average cost of $190.64 per share, for a total transaction of $1,906,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Joseph H. Boccuzi purchased 900 shares of the stock in a transaction dated Thursday, August 30th. The shares were bought at an average price of $190.59 per share, with a total value of $171,531.00. The disclosure for this purchase can be found here. Insiders have bought 11,900 shares of company stock valued at $2,234,931 over the last quarter. Company insiders own 0.36% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Zurcher Kantonalbank Zurich Cantonalbank Boosts Stake in Allergan plc (AGN)” was originally published by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.wkrb13.com/2018/11/25/zurcher-kantonalbank-zurich-cantonalbank-boosts-stake-in-allergan-plc-agn.html.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Further Reading: What are earnings reports?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.